HomeBUSINESS
BUSINESS

Tagrisso Put on Priority Path in Japan for 1st-Line EGFR-Mutated NSCLC
(Feb.6.2018)

AstraZeneca said on February 5 that the Japanese health ministry has granted priority review status to its EGFR tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) as a front-line treatment for inoperable or recurrent EGFR mutation-positive non-small cell lung cancer (NSCLC) ...
(LOG IN FOR FULL STORY)